Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00OAW
|
||||
| Former ID |
DIB009350
|
||||
| Drug Name |
DHEA
|
||||
| Synonyms |
Dehydroepiandrosterone; Fidelin; DHEA, Neuroscience Pharma; DHEA, Paladin Labs; Dehydroepiandrosterone, Neuroscience Pharma; Dehydroepiandrosterone, Paladin Labs
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cardiovascular disorder [ICD10:I00-I99] | Phase 4 | [1], [2] | ||
| Company |
Aeson Therapeutics Tucson; AZ
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H28O2
|
||||
| InChI |
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
|
||||
| InChIKey |
FMGSKLZLMKYGDP-USOAJAOKSA-N
|
||||
| CAS Number |
CAS 53-43-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
1983, 4449, 75250, 596018, 837865, 841442, 3135651, 7885884, 8145544, 8153636, 11446567, 12014907, 12146065, 14751238, 14775640, 17404931, 24278369, 24702275, 26703947, 29224908, 46387028, 46508824, 47193749, 47959958, 48413520, 48415849, 49681751, 49747225, 49857278, 50172721, 53777474, 53788218, 56312069, 56312916, 56313484, 56313819, 56320669, 56320670, 57323014, 87566797, 91692812, 92297484, 92303742, 92308678, 92309040, 92709895, 93167098, 96025095, 103302695, 104095449
|
||||
| Target and Pathway | |||||
| Target(s) | Androgen receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Pathways in cancer | |||||
| Prostate cancer | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| AndrogenReceptor Signaling Pathway | |||||
| FSH Signaling Pathway | |||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Coregulation of Androgen receptor activity | |||||
| Regulation of Androgen receptor activity | |||||
| Nongenotropic Androgen signaling | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| FOXA1 transcription factor network | |||||
| Notch-mediated HES/HEY network | |||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Integrated Pancreatic Cancer Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Nuclear Receptors | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02357472) The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2370). | ||||
| REF 3 | Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.